ArticleHuman vaccines & immunotherapeutics2026
Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network.
Marina Viñeta Paramo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it